Singota Solutions Capacity Update October 2024: Small Molecule

We recognize that as demand for cutting-edge therapeutics grows, so does the need for sophisticated drug delivery methods. In our forward-thinking presentation on the future of complex injectables and injectable formulation development, we've showcased our expertise in overcoming challenges in formulating advanced injectables, emphasizing proprietary approaches focused on precision, stability, and risk mitigation.

The presentation below covers several key topics, including the growing complexity of injectable formulations driven by new drug types and delivery platforms, as well as a detailed classification of complex injectables, such as solid nanoparticles, self-assembled liquid phases, liposomes, and microparticles. The importance of excipients in ensuring stability, efficacy, and safety was emphasized, along with optimization methodologies like Design of Experiments (DoE) and Quality-by-Design (QbD).

We've also highlighted the need to balance complexity with agility, showing how Formulation-by-Design (FbD) and DoE ensure scalability and alignment with quality requirements. Additionally, we introduce our Risk Knowledge Infinity (RKI) Cycle for systematic risk assessment and mitigation in formulation and process development. With advanced infrastructure and a comprehensive approach, see why we're well-positioned to support the development of stable, effective, and safe injectable products for advanced therapeutics.